In the past it was necessary to utilise different secondary devices for therapeutic-apheresis depending on the type of therapy and the needed adsorber.The groundbreaking innovation from medicap clinic consists in the developmentof a highly flexible system, which enables in just one secondary-device the application and the precise management of different adsorbers. At the same time - and this is yet another crucial advantage - ADAsorb® is compatible to various primary separation systems. This development makes ADAsorb® the worldwide first open secondary-system for different plasma adsorbers and thus has been encountered with great interest amongst experts. ADAsorb® simplifies the procedure significantly and reduces investment costs considerably. The diversity of treatmentoptions enables a high efficiency of the device, thus serving both the patient and the operator.

ADAsorb® – Overview Features and Advantages

• Compact and highly flexible device.
• Applicable for various indications.
• Computer managed and monitored treatments.
• Specially developed treatment software for every single
• adsorber type.
• Clearly structured menu: simple and intuitive handling
• via touch screen monitor.
• The operator is guided step by step through the treatment
• with ADAsorb®.
• Easy adjustment of therapy parameters for an optimal
• adaption to each patient.
• Text messages and information offer a clear support.
• Information box: displays the data of all performed treatment cycles.
• Treatment protocol can be saved
• Graphical presentation of the extracorporeal ADAsorb® cycle ensures an overview any time.

Advantage Overview

Convincing innovative technology

First open apheresis system worldwide, which means variousadsorber types and technologies from differentmanufactures can be managed with ADAsorb®.

Flexibility, the way you want it

Application of different adsorbers and adsorber technologies.

Compatibility with diverse primary separation systems.

Efficiency that counts
 Only one apheresis system necessary.

• reduced training time
• reduced staff
• reduced total costs

Following a range of established areas of application:

METABOLISM / LDL-Apheresis

• Familial hypercholesterolemia
• Elevated lipoprotein (a)
• Defect apolipoprotein B-100

NEPHROLOGY

• Goodpasture´s syndrome

RHEUMATOLOGY

• Systemic lupus erythematosus (SLE)
• Wegener´s granulomatosis
• Rheumatoid arthritis

TRANSPLANTATION

• HLA Hyperimmunisation
• Acute Humoral Rejection (AHR)
• AB0-incompatibility

CARDIOLOGY

• Delated Cardiomyopathy (DCM)

HAEMATOLOGY

• Acquired inhibitor against coagulation factor, i.e. Haemophilia with a factor VIII-Inhibitor
• Thrombotic Thrombocytopenic Purpura (TTP)

NEUROLOGY

• Guillain-Barré Syndrome (GBS)
• Myasthenia Gravis (MG)